Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch

Precision Peptide Clears Purity Hurdle, But Commercial Execution Risks Remain

By The Northwire Desk — AI Analysis May 19, 2026 · 07:01 BPC · 0.45 The Precision Peptide Company Inc.
Executive Summary
  • The company released independent third-party laboratory results confirming 95.5% chromatographic purity for its lead product candidate, a needle-free BPC-157 transdermal patch.
  • Testing was conducted by Miraxis Labs using UHPLC-DAD methods, exceeding the $\ge$95% industry benchmark for high-purity grade peptide products.
  • The quantified dose is confirmed at 2.02 mg of BPC-157 per patch.
  • Regulatory context indicates the FDA Pharmacy Compounding Advisory Committee will evaluate BPC-157 for inclusion on the 503A Bulks List on July 23, 2026.
  • The company intends to progress toward commercial release subject to additional testing and manufacturing scale-up.
  • This news follows a strategic marketing partnership announced May 12 with Mixed Martial Arts Group Limited (MMA) to market peptide products to MMA's global ecosystem.
Material Impact
  • Validation of Product Viability: The independent lab results de-risk the commercial launch by confirming quality standards are met, which is critical for consumer trust in a wellness/peptide product.
  • Incremental vs. New Information: While positive, this news was anticipated following the May 7 update stating "results expected in the near term." It confirms execution rather than introducing a new strategic pivot like the MMA partnership did on May 12.
  • Revenue Catalyst Linkage: The purity data supports the validity of the revenue-generating vertical established with MMA, but does not itself generate immediate cash flow.
  • Regulatory Dependency: Commercial launch remains contingent on the July 23 FDA PCAC evaluation; this news clears a quality hurdle but not the regulatory one.
  • Market Expectation: The stock price has already reacted to the May 12 partnership (rising to $0.51), suggesting some of the commercial optimism is priced in, making this validation routine rather than game-changing.
BPC · Price
Company Overview
  • Company: The Precision Peptide Company Inc. (CSE: BPC).
  • Flagship Project: Needle-free BPC-157 transdermal patch designed to eliminate injections, reconstitution, and sterile handling barriers for peptide therapy.
  • Subsidiary: Amino Innovations manages the existing oral peptide line and the new delivery technology platform.
  • Development Stage: Lead product has cleared independent purity testing; awaiting regulatory inclusion on FDA 503A Bulks List for commercial launch.
  • Second Product: Immune Defense Patch (Thymosin Alpha-1) is in development on the same delivery platform.
Read the original news release →

More from The Precision Peptide Company Inc.

Jun 23, 2026 · 07:31

Compliance milestones unlock e-commerce scaling, but regulatory clarity remains the true catalyst.

Other Jun 11, 2026 · 17:01

Pre-revenue peptide developer secures at-market capital to fund U.S. commercial rollout amid regulatory tailwinds.

Financings Jun 09, 2026 · 07:31

Building compliant U.S. telehealth and compounding infrastructure ahead of pivotal July FDA PCAC review.

M&A / Property Jun 02, 2026 · 07:01

The Precision Peptide Company Inc.

Financings May 26, 2026 · 07:31

Precision Peptide Advances Commercial Launch with MMA Partnership Backing

Other May 21, 2026 · 09:00

McGregor and Trump Jr. muscle into peptide marketing pact, but needle-free patch launch remains the real prize

Financings